Matches in Wikidata for { <http://www.wikidata.org/entity/Q99631295> ?p ?o ?g. }
- Q99631295 description "article scientifique publié en 2020" @default.
- Q99631295 description "articolo scientifico (pubblicato il 2020)" @default.
- Q99631295 description "artikull shkencor i botuar më 01 janar 2020" @default.
- Q99631295 description "artículu científicu espublizáu en xineru de 2020" @default.
- Q99631295 description "im Januar 2020 veröffentlichter wissenschaftlicher Artikel" @default.
- Q99631295 description "scientific article published on 01 January 2020" @default.
- Q99631295 description "wetenschappelijk artikel" @default.
- Q99631295 description "наукова стаття, опублікована 1 січня 2020" @default.
- Q99631295 description "научна статия" @default.
- Q99631295 name "Days gained response discriminates treatment response in patients with recurrent glioblastoma receiving bevacizumab-based therapies" @default.
- Q99631295 name "Days gained response discriminates treatment response in patients with recurrent glioblastoma receiving bevacizumab-based therapies" @default.
- Q99631295 name "Days gained response discriminates treatment response in patients with recurrent glioblastoma receiving bevacizumab-based therapies" @default.
- Q99631295 type Item @default.
- Q99631295 label "Days gained response discriminates treatment response in patients with recurrent glioblastoma receiving bevacizumab-based therapies" @default.
- Q99631295 label "Days gained response discriminates treatment response in patients with recurrent glioblastoma receiving bevacizumab-based therapies" @default.
- Q99631295 label "Days gained response discriminates treatment response in patients with recurrent glioblastoma receiving bevacizumab-based therapies" @default.
- Q99631295 prefLabel "Days gained response discriminates treatment response in patients with recurrent glioblastoma receiving bevacizumab-based therapies" @default.
- Q99631295 prefLabel "Days gained response discriminates treatment response in patients with recurrent glioblastoma receiving bevacizumab-based therapies" @default.
- Q99631295 prefLabel "Days gained response discriminates treatment response in patients with recurrent glioblastoma receiving bevacizumab-based therapies" @default.
- Q99631295 P1433 Q99631295-1CA66CDA-7D85-4D95-A7F1-7565AEB237D6 @default.
- Q99631295 P1476 Q99631295-6D866A9F-54CD-4D9E-928C-B98DD5161BFE @default.
- Q99631295 P2093 Q99631295-280DB65D-195F-497B-BBB3-15F532F4D0B6 @default.
- Q99631295 P2093 Q99631295-51A13FCA-0ACD-4FD3-A0FE-07EA4052BF95 @default.
- Q99631295 P2093 Q99631295-5D4CFC77-2DC6-4451-A8F8-69E59C102362 @default.
- Q99631295 P2093 Q99631295-5D824C49-48C6-4095-8692-3FB248C98A25 @default.
- Q99631295 P2093 Q99631295-975DA8E8-6B7C-4C2A-B461-CDA4CDE39FC2 @default.
- Q99631295 P2093 Q99631295-BC99B1B5-F789-4CF0-A8E6-2F82FDF277AC @default.
- Q99631295 P2093 Q99631295-DE1FAC16-E6B7-4A0B-944A-1F1CB2CD341E @default.
- Q99631295 P2093 Q99631295-EDD42F09-77CB-44A0-A4B1-7BF9EA387E71 @default.
- Q99631295 P2093 Q99631295-F9DBCE91-D20A-4095-822C-E53F4EF20A2F @default.
- Q99631295 P275 Q99631295-2cbecba1-4017-42af-8c14-1bdc523e06b6 @default.
- Q99631295 P2860 Q99631295-05BCF288-E5EC-41AF-A610-472E48AADC79 @default.
- Q99631295 P2860 Q99631295-062B7FD4-29AA-43DF-B976-BABC326E2C5B @default.
- Q99631295 P2860 Q99631295-07E91907-9BDD-4936-8CAB-A2F29E0BBC41 @default.
- Q99631295 P2860 Q99631295-0BA629E6-DB29-4F76-8691-44CD040AED94 @default.
- Q99631295 P2860 Q99631295-2787C711-34EB-4767-93B4-B6A2AD022E1E @default.
- Q99631295 P2860 Q99631295-2DF18ABE-F1D0-4256-87AB-4BF2689204A4 @default.
- Q99631295 P2860 Q99631295-40410F01-1277-4172-A78E-F5782F512EF4 @default.
- Q99631295 P2860 Q99631295-47EB167E-4C80-475C-B2BA-E3F78D54B620 @default.
- Q99631295 P2860 Q99631295-5F665E21-FA94-4320-B56F-1422E4963E50 @default.
- Q99631295 P2860 Q99631295-6858695D-F5EF-45CC-9913-975011CD3BB1 @default.
- Q99631295 P2860 Q99631295-6C127872-1063-4E98-AAB9-D026E0C14DE4 @default.
- Q99631295 P2860 Q99631295-6EC14FA3-2E7C-4EA3-8AB7-364EC7781B5E @default.
- Q99631295 P2860 Q99631295-79B8FDF4-BE31-4AF2-82B3-7285285C350E @default.
- Q99631295 P2860 Q99631295-831E224F-8E89-4EB5-84DC-7D050702E050 @default.
- Q99631295 P2860 Q99631295-93C48A2F-7611-4CA9-A847-736D59F08E1E @default.
- Q99631295 P2860 Q99631295-A2C34A04-3449-4F90-99DA-E57CFA06EE3F @default.
- Q99631295 P2860 Q99631295-A417A35B-C39E-4C22-AC09-EC22A0FE6F57 @default.
- Q99631295 P2860 Q99631295-ABCE50CE-C69F-4446-8991-71CE157517F9 @default.
- Q99631295 P2860 Q99631295-C964E2EE-A2EB-4B2C-9B31-C27FEABAA0EF @default.
- Q99631295 P2860 Q99631295-CFF4B2D6-531A-4A11-A43D-FA8F451082BF @default.
- Q99631295 P2860 Q99631295-D90B2BB0-8067-4400-8196-DDD7927C87CC @default.
- Q99631295 P2860 Q99631295-DEA8368D-6C54-4B57-94EB-1C47FA97BEB0 @default.
- Q99631295 P2860 Q99631295-E745F796-8AEE-4EE8-9A94-F734F061729B @default.
- Q99631295 P2860 Q99631295-E8C9602A-BA22-4844-B120-970F775AEE06 @default.
- Q99631295 P2860 Q99631295-EF1AA584-1ACD-43FA-BFE4-22C11DE041DF @default.
- Q99631295 P2860 Q99631295-F9697C67-9373-482C-96F5-3F9FF9C9A120 @default.
- Q99631295 P2860 Q99631295-FAB2F712-0637-4455-AD18-FB27A5BC9503 @default.
- Q99631295 P304 Q99631295-2340AE09-0F51-42AF-B1C4-6E664861FC1F @default.
- Q99631295 P31 Q99631295-2144B530-6E72-4083-ABD2-62B112243F42 @default.
- Q99631295 P356 Q99631295-BEAD61F2-D7FC-4D8A-8E8D-B965F52E8D8B @default.
- Q99631295 P433 Q99631295-5A1C2CD2-722D-4B65-BDDC-3AB2A62B271B @default.
- Q99631295 P478 Q99631295-F07BEB8C-5893-4AAD-A5B1-57882EBCAF04 @default.
- Q99631295 P50 Q99631295-7216AF34-1EFB-451A-A075-35EA968A1B52 @default.
- Q99631295 P50 Q99631295-B8CC9264-D829-46AD-9925-9825C2FA1DEB @default.
- Q99631295 P577 Q99631295-BD438A21-A375-4B4B-8C99-31965BB50DB6 @default.
- Q99631295 P6216 Q99631295-0b1d841a-18eb-4a98-9945-9a97359c555e @default.
- Q99631295 P698 Q99631295-0E9623EE-8035-4158-B7E4-BE00B60FBAD0 @default.
- Q99631295 P921 Q99631295-8F69CB05-5FBA-40D1-A33B-FA816B6DFA56 @default.
- Q99631295 P932 Q99631295-C1E0F5E8-3417-4E5B-977A-687457EC9655 @default.
- Q99631295 P356 VDAA085 @default.
- Q99631295 P698 32864609 @default.
- Q99631295 P1433 Q68835862 @default.
- Q99631295 P1476 "Days gained response discriminates treatment response in patients with recurrent glioblastoma receiving bevacizumab-based therapies" @default.
- Q99631295 P2093 "Alyx B Porter" @default.
- Q99631295 P2093 "Cassandra R Rickertsen" @default.
- Q99631295 P2093 "Gustavo De Leon" @default.
- Q99631295 P2093 "Kamala R Clark-Swanson" @default.
- Q99631295 P2093 "Kristin R Swanson" @default.
- Q99631295 P2093 "Leland S Hu" @default.
- Q99631295 P2093 "Maciej M Mrugala" @default.
- Q99631295 P2093 "Sandra K Johnston" @default.
- Q99631295 P2093 "Scott A Whitmire" @default.
- Q99631295 P275 Q20007257 @default.
- Q99631295 P2860 Q27860904 @default.
- Q99631295 P2860 Q27860910 @default.
- Q99631295 P2860 Q28131668 @default.
- Q99631295 P2860 Q29617568 @default.
- Q99631295 P2860 Q33382596 @default.
- Q99631295 P2860 Q33828439 @default.
- Q99631295 P2860 Q34117487 @default.
- Q99631295 P2860 Q34570841 @default.
- Q99631295 P2860 Q35800569 @default.
- Q99631295 P2860 Q36699985 @default.
- Q99631295 P2860 Q37088426 @default.
- Q99631295 P2860 Q37206334 @default.
- Q99631295 P2860 Q38773624 @default.
- Q99631295 P2860 Q38829244 @default.
- Q99631295 P2860 Q38855020 @default.
- Q99631295 P2860 Q40405075 @default.